IDYA

Company Overview — What Does IDEAYA Biosciences, Inc. Do?

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. IDEAYA Biosciences, Inc. (IDYA) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Yujiro S. Hata and employs approximately 80 people. With a market capitalization of $2.9B, IDYA is one of the notable companies in the Healthcare sector.

IDEAYA Biosciences, Inc. (IDYA) Stock Rating — Reduce (April 2026)

As of April 2026, IDEAYA Biosciences, Inc. receives a Reduce rating with a composite score of 36.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.IDYA ranks #2,567 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, IDEAYA Biosciences, Inc. ranks #332 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

IDYA Stock Price and 52-Week Range

IDEAYA Biosciences, Inc. (IDYA) currently trades at $36.54. The stock gained $5.54 (17.9%) in the most recent trading session. The 52-week high for IDYA is $39.28, which means the stock is currently trading -7.0% from its annual peak. The 52-week low is $13.45, putting the stock 171.7% above its annual trough. Recent trading volume was 1.5M shares, reflecting moderate market activity.

Is IDYA Overvalued or Undervalued? — Valuation Analysis

IDEAYA Biosciences, Inc. (IDYA) carries a value factor score of 28/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 5.00x, compared to the Healthcare sector average of 23.63x — a discount of 79%. The price-to-book ratio stands at 2.65x, versus the sector average of 2.75x. The price-to-sales ratio is 13.06x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, IDYA trades at 5.55x EV/EBITDA, versus 6.34x for the sector.

At current multiples, IDEAYA Biosciences, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

IDEAYA Biosciences, Inc. Profitability — ROE, Margins, and Quality Score

IDEAYA Biosciences, Inc. (IDYA) earns a quality factor score of 30/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -8.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -7.4% versus the sector average of -33.1%.

On a margin basis, IDEAYA Biosciences, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is 52.2% (sector: -66.1%). Net profit margin stands at 57.4%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

IDYA Debt, Balance Sheet, and Financial Health

IDEAYA Biosciences, Inc. has a debt-to-equity ratio of 8.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 11.34x, indicating strong short-term liquidity. Cash and equivalents stand at $299M.

IDYA has a beta of 1.40, meaning it is more volatile than the broader market — a $10,000 investment in IDYA would be expected to move 39.7% more than the S&P 500 on any given day. The stability factor score for IDEAYA Biosciences, Inc. is 55/100, reflecting average volatility within the normal range for its sector.

IDEAYA Biosciences, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, IDEAYA Biosciences, Inc. reported revenue of $208M and earnings per share (EPS) of $-1.28. Net income for the quarter was $-82M. Operating income came in at $-132M.

In FY 2025, IDEAYA Biosciences, Inc. reported revenue of $219M and earnings per share (EPS) of $-1.28. Net income for the quarter was $-114M. Revenue grew 3024.4% year-over-year compared to FY 2024. Operating income came in at $-159M.

In Q3 2025, IDEAYA Biosciences, Inc. reported revenue of $208M and earnings per share (EPS) of $1.35. Net income for the quarter was $119M. Operating income came in at $108M.

In Q2 2025, IDEAYA Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.88. Net income for the quarter was $-77M. Operating income came in at $-89M.

Over the past 8 quarters, IDEAYA Biosciences, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $208M. Investors analyzing IDYA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

IDYA Dividend Yield and Income Analysis

IDEAYA Biosciences, Inc. (IDYA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

IDYA Momentum and Technical Analysis Profile

IDEAYA Biosciences, Inc. (IDYA) has a momentum factor score of 62/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 2/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

IDYA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, IDEAYA Biosciences, Inc. (IDYA) ranks #332 out of 838 stocks based on the Blank Capital composite score. This places IDYA in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing IDYA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IDYA vs S&P 500 (SPY) comparison to assess how IDEAYA Biosciences, Inc. stacks up against the broader market across all factor dimensions.

IDYA Next Earnings Date

No upcoming earnings date has been announced for IDEAYA Biosciences, Inc. (IDYA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy IDYA? — Investment Thesis Summary

The quantitative profile for IDEAYA Biosciences, Inc. suggests caution. The quality score of 30/100 flags below-average profitability. The value score of 28/100 indicates premium valuation. Price momentum is positive at 62/100, suggesting the trend favors buyers.

In summary, IDEAYA Biosciences, Inc. (IDYA) earns a Reduce rating with a composite score of 36.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IDYA stock.

Related Resources for IDYA Investors

Explore more research and tools: IDYA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare IDYA head-to-head with peers: IDYA vs AZN, IDYA vs SLGL, IDYA vs VMD.